Galapagos' evolution inflection

Data next month for filgotinib will be the first near-term opportunity for Galapagos N.V. to show it can complete its shift from hybrid discovery/service company into a product-focused play.

The Janus kinase-1 (JAK-1) inhibitor will produce data this year from a series of Phase II trials in RA and Crohn's disease. Good results would trigger AbbVie Inc.'s option to the program, bringing in cash to support the unpartnered clinical and preclinical programs in Galapagos' pipeline...